Literature DB >> 22020901

Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients.

Jeffrey R Curtis1, Shih-Yin Chen, Winifred Werther, Ani John, David A Johnson.   

Abstract

PURPOSE: To validate, using physician review of abstracted medical chart data as a gold standard, a claims-based algorithm developed to identify gastrointestinal (GI) perforation cases among rheumatoid arthritis (RA) patients.
METHODS: Patients with established RA, aged 18 years or older with hospital admissions between January 2004 and September 2009, were selected from a large US-hospital-based database. An algorithm with International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes for GI perforation and combinations of GI-related diagnosis codes and Current Procedural Terminology (CPT-4) procedure codes for relevant GI surgeries was used to identify potential GI perforation cases. Two senior experienced specialist physicians independently reviewed abstracted chart data and classified cases as confirmed or unconfirmed GI perforations. Positive predictive values (PPVs) to identify confirmed GI perforation were calculated and stratified by upper versus lower GI tract.
RESULTS: Overall, 86 of 92 GI perforation cases were confirmed, yielding an overall PPV of 94% (95%confidence interval [CI] = 86%-98%). PPV was 100% (95%CI = 100%-100%) for upper GI perforation (esophagus, stomach) and 91% (95%CI = 90%-97%) for lower GI perforation (small intestine, PPV = 100%; large intestine, PPV = 94%; unspecified lower GI, PPV = 89%).
CONCLUSIONS: This algorithm, consisting of a combination of ICD-9-CM diagnosis and CPT-4 codes, could be used in future safety studies to evaluate GI perforation risk factors in RA patients.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22020901      PMCID: PMC3227025          DOI: 10.1002/pds.2215

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  31 in total

1.  Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database.

Authors:  C Cattaruzzi; M G Troncon; L Agostinis; L A García Rodríguez
Journal:  J Clin Epidemiol       Date:  1999-06       Impact factor: 6.437

Review 2.  Lessons for inflammatory bowel disease from rheumatology.

Authors:  J M Rhodes; P Collins
Journal:  Dig Liver Dis       Date:  2005-11-08       Impact factor: 4.088

3.  Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes.

Authors:  Lindsey A Criswell; Kirsten A Pfeiffer; Raymond F Lum; Bonnie Gonzales; Jill Novitzke; Marlena Kern; Kathy L Moser; Ann B Begovich; Victoria E H Carlton; Wentian Li; Annette T Lee; Ward Ortmann; Timothy W Behrens; Peter K Gregersen
Journal:  Am J Hum Genet       Date:  2005-02-17       Impact factor: 11.025

4.  Safety of long-term tacrolimus therapy for rheumatoid arthritis: an open-label, uncontrolled study in non-elderly patients.

Authors:  Shinichi Kawai; Kortaro Tanaka; Iwao Ohno; Kazunori Utsunomiya; Yoshihiko Seino
Journal:  Mod Rheumatol       Date:  2008-04-22       Impact factor: 3.023

Review 5.  Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs.

Authors:  L Laine; R Smith; K Min; C Chen; R W Dubois
Journal:  Aliment Pharmacol Ther       Date:  2006-09-01       Impact factor: 8.171

6.  Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study.

Authors:  Lisa F Barcellos; Brinda B Kamdar; Patricia P Ramsay; Cari DeLoa; Robin R Lincoln; Stacy Caillier; Silke Schmidt; Jonathan L Haines; Margaret A Pericak-Vance; Jorge R Oksenberg; Stephen L Hauser
Journal:  Lancet Neurol       Date:  2006-11       Impact factor: 44.182

7.  Validation of administrative data used for the diagnosis of upper gastrointestinal events following nonsteroidal anti-inflammatory drug prescription.

Authors:  N S Abraham; D C Cohen; B Rivers; P Richardson
Journal:  Aliment Pharmacol Ther       Date:  2006-07-15       Impact factor: 8.171

Review 8.  TNF-mediated inflammatory disease.

Authors:  J R Bradley
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

Review 9.  Hyperhomocysteinemia, inflammation and autoimmunity.

Authors:  Pietro Enea Lazzerini; Pier Leopoldo Capecchi; Enrico Selvi; Sauro Lorenzini; Stefania Bisogno; Mauro Galeazzi; Franco Laghi Pasini
Journal:  Autoimmun Rev       Date:  2007-04-05       Impact factor: 9.754

10.  Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002.

Authors:  Russell Cohen; Don Robinson; Clark Paramore; Kathy Fraeman; Kevin Renahan; Mohan Bala
Journal:  Inflamm Bowel Dis       Date:  2008-06       Impact factor: 5.325

View more
  9 in total

1.  Characterizing Health Outcomes in Idiopathic Pulmonary Fibrosis using US Health Claims Data.

Authors:  Kathleen M Mortimer; Dorothee B Bartels; Nadine Hartmann; Jorge Capapey; Jing Yang; Robert Gately; Cheryl Enger
Journal:  Respiration       Date:  2020-01-24       Impact factor: 3.580

2.  Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis.

Authors:  Jeffrey R Curtis; Angel Lanas; Ani John; David A Johnson; Kathy L Schulman
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-12       Impact factor: 4.794

Review 3.  Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians.

Authors:  Aprajita Jagpal; Jeffrey R Curtis
Journal:  Drug Saf       Date:  2018-06       Impact factor: 5.606

4.  Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.

Authors:  Fenglong Xie; Huifeng Yun; Sasha Bernatsky; Jeffrey R Curtis
Journal:  Arthritis Rheumatol       Date:  2016-11       Impact factor: 10.995

5.  Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis.

Authors:  Jeffrey R Curtis; John W Baddley; Shuo Yang; Nivedita Patkar; Lang Chen; Elizabeth Delzell; Ted R Mikuls; Kenneth G Saag; Jasvinder Singh; Monika Safford; Grant W Cannon
Journal:  Arthritis Res Ther       Date:  2011-09-20       Impact factor: 5.156

6.  Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources.

Authors:  Sharareh Monemi; Erhan Berber; Khaled Sarsour; Jianmei Wang; Kathy Lampl; Kamal Bharucha; Attila Pethoe-Schramm
Journal:  Rheumatol Ther       Date:  2016-07-15

7.  Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study.

Authors:  Andrei Barbulescu; Bénédicte Delcoigne; Johan Askling; Thomas Frisell
Journal:  RMD Open       Date:  2020-07

8.  An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.

Authors:  Gerd R Burmester; Jeffrey R Curtis; Huifeng Yun; Oliver FitzGerald; Kevin L Winthrop; Valderilio F Azevedo; William F C Rigby; Keith S Kanik; Cunshan Wang; Pinaki Biswas; Thomas Jones; Niki Palmetto; Thijs Hendrikx; Sujatha Menon; Ricardo Rojo
Journal:  Drug Saf       Date:  2020-04       Impact factor: 5.606

9.  Comparison of the risk of gastrointestinal perforation between patients with and without rheumatoid arthritis: A nationwide cohort study in Asia.

Authors:  Ting-Chia Chang; Wei-Chih Kan; Kuo-Chen Cheng; Chung-Han Ho; Yi-Chen Chen; Chin-Chen Chu; Chien-Chin Hsu; Hsing-Tao Kuo; Hung-Jung Lin; Chien-Cheng Huang
Journal:  Front Med (Lausanne)       Date:  2022-09-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.